Cargando…

Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic

With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it is that, in a world of evolvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshiraihi, Ilham M., Klein, Gerald L., Brown, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930934/
https://www.ncbi.nlm.nih.gov/pubmed/33535388
http://dx.doi.org/10.3390/diseases9010012
_version_ 1783660186299269120
author Alshiraihi, Ilham M.
Klein, Gerald L.
Brown, Mark A.
author_facet Alshiraihi, Ilham M.
Klein, Gerald L.
Brown, Mark A.
author_sort Alshiraihi, Ilham M.
collection PubMed
description With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it is that, in a world of evolving zoonotic viruses, we must be better prepared for the next deadly outbreak. While the acute nature of the COVID-19 pandemic demanded a highly specific approach, it is advisable to consider the breadth of seemingly endless possibilities in our approach to managing the next inevitable occurrence of an outbreak. Though there is little chance of discovering a “magic pill” to combat all future pathogens, the highly conserved nature of non-surface viral proteins exposes an “Achilles’ heel” in the structural genome of viral pathogens. Herein, we consider the potential of targeting such proteins to develop broad-spectrum therapeutics for the future. To illustrate this point, we outline the therapeutic potential of targeting the nonstructural protein 16 methyltransferase, which is conserved across most coronaviruses.
format Online
Article
Text
id pubmed-7930934
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79309342021-03-05 Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic Alshiraihi, Ilham M. Klein, Gerald L. Brown, Mark A. Diseases Editorial With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it is that, in a world of evolving zoonotic viruses, we must be better prepared for the next deadly outbreak. While the acute nature of the COVID-19 pandemic demanded a highly specific approach, it is advisable to consider the breadth of seemingly endless possibilities in our approach to managing the next inevitable occurrence of an outbreak. Though there is little chance of discovering a “magic pill” to combat all future pathogens, the highly conserved nature of non-surface viral proteins exposes an “Achilles’ heel” in the structural genome of viral pathogens. Herein, we consider the potential of targeting such proteins to develop broad-spectrum therapeutics for the future. To illustrate this point, we outline the therapeutic potential of targeting the nonstructural protein 16 methyltransferase, which is conserved across most coronaviruses. MDPI 2021-02-01 /pmc/articles/PMC7930934/ /pubmed/33535388 http://dx.doi.org/10.3390/diseases9010012 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Alshiraihi, Ilham M.
Klein, Gerald L.
Brown, Mark A.
Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title_full Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title_fullStr Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title_full_unstemmed Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title_short Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
title_sort targeting nsp16 methyltransferase for the broad-spectrum clinical management of coronaviruses: managing the next pandemic
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930934/
https://www.ncbi.nlm.nih.gov/pubmed/33535388
http://dx.doi.org/10.3390/diseases9010012
work_keys_str_mv AT alshiraihiilhamm targetingnsp16methyltransferaseforthebroadspectrumclinicalmanagementofcoronavirusesmanagingthenextpandemic
AT kleingeraldl targetingnsp16methyltransferaseforthebroadspectrumclinicalmanagementofcoronavirusesmanagingthenextpandemic
AT brownmarka targetingnsp16methyltransferaseforthebroadspectrumclinicalmanagementofcoronavirusesmanagingthenextpandemic